Prof Leann Tilley’s work an example of Impact, Advancing Health 2030 Strategy in action

Prof Leann Tilley’s antimalarial work was recently highlighted by MDHS as an example of the Impact our researchers make- and forms part of the commitment to promoting the Advancing Health 2030 strategy.

The MDHS communications team chose to highlight Leann’s work as an example of making an impact through collaboration, innovation and nurturing people and their ideas through short impact stories.

Prof Leann Tilley, Dept of Biochemistry and Pharmacology, is part of an international research team working to address global concerns that current antimalarial treatments are rapidly losing their effectiveness.

Professor Tilley and colleagues have published a world-first discovery in the journal Science showing that a previously overlooked class of chemicals – known as nucleoside sulfamates or “nukes” – can cause malaria parasite enzymes involved in protein synthesis to self-destruct.

This discovery marks an important milestone and will form the basis of the development of a new antimalarial drug candidate.

The impact story highlights this new approach also has potential to open new drug discovery pathways for other diseases like cancer, neurodegenerative disease, metabolic syndromes and autoimmune disorders.

Read the short Impact Story

The Pursuit article, The new weapon against Malaria’s drug resistance, written by the SBS MarComms team highlights how this research has opened several important new drug discovery avenues to help address the deadly impact of malaria and other infectious diseases, particularly in developing nations.